Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways
-
Published:2021-06-05
Issue:9
Volume:21
Page:747-758
-
ISSN:1530-7905
-
Container-title:Cardiovascular Toxicology
-
language:en
-
Short-container-title:Cardiovasc Toxicol
Author:
Barış Veysel ÖzgürORCID, Dinçsoy Adnan Berk, Gedikli Esra, Zırh Selim, Müftüoğlu Sevda, Erdem Ayşen
Funder
Turkish Cardiovascular Academia Society
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine,Toxicology,Molecular Biology
Reference61 articles.
1. Grempler, R., Thomas, L., Eckhardt, M., Himmelsbach, F., Sauer, A., Sharp, D. E., Bakker, R. A., Mark, M., Klein, T., & Eickelmann, P. (2012). Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: Characterisation and comparison with other SGLT-2 inhibitors. Diabetes, Obesity & Metabolism, 14(1), 83–90. 2. Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine, 373(22), 2117–2128. 3. Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., & Jamal, W. (2020). Cardiovascular and renal outcomes with empagliflozin in heart failure. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2022190 4. Cherney, D. Z., Perkins, B. A., Soleymanlou, N., Har, R., Fagan, N., Johansen, O. E., Woerle, H. J., Eynatten, M., & Broedl, U. C. (2014). The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovascular Diabetology, 13, 28. 5. Barnett, A. H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H. J., & Broedl, U. C. (2014). Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: A randomised, double-blind, placebo-controlled trial. The Lancet Diabetes and Endocrinology, 2(5), 369–384.
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|